Reshaping the HIV treatment and prevention landscape

Focusing in key therapeutic areas Vaccines Resource allocation Innovation focus Infectious Diseases HIV Specialty Medicines Capital investment Oncology Immunology/ Respiratory Opportunity Driven* Major unmet patient needs and significant growth opportunities High innovation potential and first-in-class/best-in-class focus *Includes high-potential late-stage pipeline assets and internally/externally sourced assets consistent with R&D focus on the science of the immune system and human genetics gsk 17

View entire presentation